Journal article

Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis

Pasquale Rescigno, David Dolling, Vincenza Conteduca, Mattia Rediti, Diletta Bianchini, Cristian Lolli, Michael Ong, Haoran Li, Aurelius G Omlin, Sabine Schmid, Orazio Caffo, Andrea Zivi, Carmel J Pezaro, Courtney Morley, David Olmos, Nuria Romero-Laorden, Elena Castro, Maria Saez, Niven Mehra, Stella Smeenk Show all



BACKGROUND: Declines in prostate-specific antigen (PSA) levels at 12wk are used to evaluate treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by ≥30% at 4wk (PSA4w30) has been reported to be associated with better outcome in a single-centre cohort study. OBJECTIVE: To evaluate clinical relevance of early PSA decline in mCRPC patients treated with next-generation hormonal treatments (NGHTs) such as abiraterone and enzalutamide. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective multicentre analysis. Eligible patients received NGHT for mCRPC between 6 January 2006 and 31 December 2017 in 13 cancer centres worldwide, and had PSA levels assessed at ..

View full abstract